Pediatric Cardiology News

Social deprivation and environmental pollutant exposure are potential risk factors for live-born congenital heart disease in California, indicating that harmful toxins may be prevalent in at-risk communities, researchers reported.

A draft recommendation from the U.S. Preventive Services Task Force stated there is insufficient evidence of benefits or harms to support screening for high BP in asymptomatic children and adolescents.

Individuals who began smoking at a younger age were more likely to be daily smokers as adults and less likely to have quit smoking by their 40s, according to findings from the International Childhood Cardiovascular Cohort published in the Journal of the American Heart Association.

CHF Solutions announced the FDA cleared its ultrafiltration device for the treatment of hypervolemia in adults and pediatric patients who weigh 20 kg or more.

The risk for congenital heart disease-related infant mortality was higher when mothers lived farther from specialized pediatric cardiac centers, according to a research letter published in Circulation.

A recent study published in the Annals of Thoracic Surgery found that cardiac allografts from high-risk donors implanted in children resulted in similar posttransplant survival as those from low-risk donors.

Artificial intelligence-based analysis of chest X-rays was able to successfully predict the pulmonary to systemic flow ratio in patients with congenital heart disease with greater efficacy than trained pediatric cardiologists, according to findings published in JAMA Cardiology.

Outcomes after cardiac surgery improved at children’s hospitals that participated in a quality improvement collaborative, according to a study published in the Journal of the American College of Cardiology.

Breakthroughs in the detection and treatment of congenital heart defects have greatly improved the prognosis for affected children. More than 90% of infants born with congenital heart disease survive into adulthood.

Safety and efficacy of udenafil (Mezzion Pharma) for the treatment of adolescents who underwent the Fontan procedure.